BPC-157: angiogenesis, NO pathway, and systemic tissue repair BPC-157s mechanism is less centered on ECM modulation and more centered on vascular and growth-factor-signaling effects that support systemic tissue-repair outcomes
FDA Approval Criteria: For FDA approval as weight loss medication, drugs must demonstrate: Efficacy Requirements: At least 5% average weight loss greater than placebo At least 35% of patients lose 5% body weight At least 15% of patients lose 10% body weight Safety Requirements: Acceptable safety profile in clinical trials Benefits outweigh risks Appropriate for long-term use All newer GLP-1 medications far exceed the minimum efficacy requirements, which explains their dominance
We work with each patient on the most consistent schedule for their lifestyle
it is the combination of monthly cost, medication source, oversight model, and whether your dose is anchored to your biology
Facilitates muscle movement, electrolyte balancing inside muscle cells, and fatigue reduction after exercising